Novel non-antibiotic strategy against ogip infections based on an activated cereal product or ferric quinate

• US 20040265427A1
• Filed: 05/06/2004
• Published: 12/30/2004
• Est. Priority Date: 11/07/2001
• Status: Abandoned Application

• Current Assignee: Thomas Boren
• Original Assignee: Thomas Boren
• Inventors: Boren, Thomas
• Application Number:
  US10/493,220
• Publication Number:
  US 20040265427A1
• Time in Patent Office: Days
• US Class Current: 426/52
• CPC Class Codes: A23K 10/12 by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
• CPC Class Codes: A23K 10/37 from waste material from hydrolysates of wood or straw A23K10/32; from molasses A23K10/33
• CPC Class Codes: A23K 20/30 Oligoelements
• CPC Class Codes: A23K 50/10 for ruminants
• CPC Class Codes: A23K 50/30 for swines
• CPC Class Codes: A23K 50/40 for carnivorous animals, e.g. cats or dogs
• CPC Class Codes: A23K 50/75 for poultry
• CPC Class Codes: A23L 2/52 Adding ingredients adding preservatives A23L2/44
• CPC Class Codes: A23L 33/16 Inorganic salts, minerals or trace elements
• CPC Class Codes: A23L 7/104 Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
• CPC Class Codes: A23L 7/115 Cereal fibre products, e.g. bran, husk
• CPC Class Codes: A23V 2400/133 Curvatus
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 36/899 Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C12N 1/205 : Bacterial isolates
• CPC Class Codes: C12R 2001/225 : Lactobacillus
• CPC Class Codes: Y02P 60/87 : Re-use of by-products of food processing for fodder production

Abstract

The present invention refers to a non-antibiotic therapeutic strategy for inhibiting oro-gastro-intestinal infections and pathogens in general and particularly Heliobacter pylori adherence and colonization in the gastro-intestinal channel and preventing or relieving associated oro-gastro-intestinal disease. The invention relates to methods and products based on an active cereal product or ferric quinate. The invention is also applicable to other oro-gastro-intestinal pathogens in both humans and animals.

Claims

1. A cereals fermenting microorganism, characterized by having the ability to provide, upon fermentation of the cereal, activated products derived from the cereal and being inhibitors of the adherence and colonization of oro-gastro-intestinal pathogens (OGIP) in humans and animals.

2. The microorganism of claim 1, characterized in that the cereal is rye bran.

3. The microorganism of claim 2, characterized by being selected from Lactobacillus species.

4. The microorganism of claim 3, characterized by being selected from Lactobacillus curvatus strains.

5. The microorganism of claim 4, characterized by being Lactobacillus curvatus strain Lb14 deposited at Deutsche Sammlung von Mikroorganismen und Zelikulturen (DSMZ) under accession number 13890.

6. The microorganism of claim 1, characterized in producing, upon fermentation of the cereal, an activated cereal product against OGIP infections by Helicobacter pylori, Candida albicans and Streptococcus mutans in humans and Escherichia coli and Clostridium perfringens in domestic and pet animals.

7. Fermented cereal product, characterized by being obtained by fermentation of a cereal with a microorganism of claim 1 and being an inhibitor of the adherence and colonization of OGIP in humans and animals.

8. The fermented cereal product of claim 7, characterized by being derived from rye bran.

9. The fermentation product of claim 8, characterized by being the supernatant of the fermentation broth obtained by fermentation of rye bran with the Lactobacillus curvatus strain Lb 14 (DSMZ 13890).

15. A functional food product being useful for treatment of humans and animals suffering from OGIP infections, characterized by comprising the fermented cereal product of claim 7 and/or ferric quinate and, optionally, other acceptable ingredients to form a palatable food product.

16. The functional food product of claim 15 for treatment of infections by Helicobacter pylori, Candida albicans and Streptococcus mutans in humans and infections by Escherichia coli and Clostridium perfringens in domestic and pet animals.

17. The functional food product of claim 16, characterized by comprising the fermented cereal product and/or ferric quinate.

18. The functional food product of claim 15 being a beverage, bread or muesli.

19. A method of preparing the fermented cereal product of claim 7, characterized by subjecting, under conditions suitable for providing fermentation products from the cereal being competetive inhibitors of the adherence and colonization of OGIP in humans and animals, the cereal to fermentation by a microorganism and collecting the product from the fermentation broth.

20. The method of claim 19, characterized by subjecting rye bran to fermentation.

21. The method of claim 20, characterized by subjecting rye bran to fermentation by a microorganism being selected from Lactobacillus curvatus strains.

22. The method of claim 21, characterized by subjecting rye bran to fermentation by the Lactobacillus curvatus strain Lb 14 deposited at DSMZ under accession number 13890.

23. The method of claim 22, characterized in that the collected product from the fermentation broth is the supernatant.

24. Growth promoting feedstuff supplement for domestic animals, characterized by being or comprising the fermented cereal product of claim 7 and/or ferric quinate.

25. Pharmaceutical product based on purified extracts, or fraction of extracts, and/or ferric quinate, with the H. pylori-Lewis b antigen binding inhibitory (blocking) activity as a marker for the activated inhibitor of claim 7, for treatment of humans suffering from OGIP-infections in humans and domestic animals.

26. The pharmaceutical product of claim 25 for treatment of Helicobacter pylori, Candida albicans and Streptococcus mutans infections in humans.

27. The pharmaceutical product of claim 25 for treatment of Escherichia Coli and Clostridium perfringens infections in domestic cattle, pig and poultry.

28. The pharmaceutical product of claim 25 in the form of a mouth rinse for treatment of dental caries, periodontal disease and oral malodor/halitosis.

10-14. -14. (canceled).

29. (canceled).